Adult

Nitrofurantoin

Warning

General Information

Nitrofuran antibiotic

Immediate release preparations: Formulary antimicrobial: Use in accordance with Trust guidelines. 

  • OUH only stocks immediate release preparations
  • Modified release preparations are Non-formulary. See the Therapeutic Substitution Medicines Information Leaflet.

AWaRe antibiotic classification: 'Access'. Use as per guidelines.

For all information regarding contra-indications, interactions, contraception, pregnancy and breastfeeding and additional information, see BNF and Summary of Product Characteristics (SPC).

Standard dose

 

Oral dose

Standard dose

50mg QDS

Renal and hepatic impairment

Renal impairment

  • Check renal function before starting nitrofurantoin, especially in the elderly.
  • The antibacterial efficacy of nitrofurantoin depends on adequate renal secretion into the urinary tract. Therefore, there is reduced efficacy of nitrofurantoin in renal impairment.
  • Avoid if eGFR less than 45mL/min/1.73m2.
  • HD/HDF/High Flux/PD: Contra-indicated.

 

Hepatic impairment

Use with caution. No dose adjustment required.

  • Hepatic reactions including cholestatic jaundice, autoimmune hepatitis and chronic active hepatitis and hepatic necrosis have been reported with the use of nitrofurantoin.

  • Be vigilant for symptoms and signs of liver dysfunction in patients taking nitrofurantoin for any duration, but particularly with long-term use, and monitor patients periodically for signs of hepatitis and for changes in biochemical tests that would indicate hepatitis or liver injury.
  • For more information see MHRA Drug Safety Update (April 2023) Nitrofurantoin: reminder of the risks of pulmonary and hepatic adverse drug reactions

References

Editorial Information

Last reviewed: 23 Mar 2026

Next review date: 28 Mar 2029

Author(s): AMST.